Summary.-Affinity-purified antibodies to carcinoembryonic antigen (CEA) have been injected into immune-suppressed mice bearing xenografts of human breast tumours. It has been shown that the antibodies localized in the tumours but not in normal tissues. The degree of tumour localization correlates with the amount of tumour CEA, and is unaffected by levels of circulating CEA or CEA/anti-CEA immune complexes.
THE CONCEPT of injecting anti-tumourcell antibodies to localize neoplasms was first introduced in experimental systems by Pressman (1957) . Since then, success has been achieved with human tumours using antibodies to the carcinoembryonic antigen (CEA) (Gold & Freedman, 1965) . It has been demonstrated that such radiolabelled antibodies localized preferentially in human colonic neoplasms xenografted into animals (Primus et al., 1973; Mach et al., 1974) . More recently, localization of anti-CEA antibodies has been attained in patients, but only when the blood-pool background was subtracted by a computerized technique (Goldenberg et al., 1978; Dykes et al., 1980; Mach et al., 1980) . Although some workers have achieved almost complete success with this method, others have expressed doubts as to its present suitability for routine clinical use (Mach et al., 1980) . Many breast carcinomas produce CEA, the level of circulating CEA being stagedependent (Laurence et al., 1972; Coombes et al., 1980; Tormey & Waalkes, 1978) . The need for early detection of systemic metastases and metastatic involvement of inaccessible internal mammary lymph nodes has prompted us to examine the 40 localizing potential of anti-CEA in human breast carcinomas. The establishment of xenografts of human breast carcinomas in immune-suppressed mice (Bailey et al., 1980 ) has enabled us to examine different tumours and thus investigate the kinetics of tumour lbcalization and its relationship to the CEA content of the tumour before starting clinical studies.
MATERIALS AND METHODS
Animals and tumours.-Four-week-old, female CBA/lac mice, weighing on average 20 g, were immune suppressed by thymectomy and total-body irradiation (6 gray) preceded by i.p. injection of cytosine arabinoside (200 mg/kg) (Steel et al., 1978) . Three different xenograft lines of human breast carcinomas were used (HX99, HX106 and HX104) (Bailey et al., 1981) . These have been shown to maintain their characteristic human morphology, chromosome number and tumour-marker expression throughout passaging. HX104 was used at Passage 6, HX99 at Passage 7 and 8 and HX106 at Passage 8. The tumours were implanted s.c. bilaterally in the flanks 3-5 weeks before use.
The antibody and iodine labelling.-The CEA used as immunogen and for coupling of Sepharose 4B (see below) was isolated from hepatic metastases of a human colonic carcin-oma and purified to satisfy the criteria previously described (Westwood & Thomas, 1975; Westwood, 1978) . Anti-CEA sera were raised by monthly s.c. injections of a goat with 100 jug of CEA, emulsified with Freund's adjuvant. The first 2 CEA injections were in complete adjuvant. Regular bleeds were taken after the 4th injection, and the goat was exsanguinated 2 weeks after the 7th injection. The y-globulin fraction of the immune serum was obtained and the solution, in phosphate-buffered saline (PBS) (015M, pH 7) was passed over a column comprising CEA (15 mg) covalently bound to Sepharose 4B (10 ml). The column was washed with 01M PBS to remove all unbound protein, and anti-CEA antibodies were recovered from the column using 6M guanidine HCI in 01M PBS. The guanidine HCI was removed by dialysis.
The affinity-purified goat anti-CEA antibodies were labelled with 125I, using chloramine-T (Greenwood et al., 1963 (1974) except that the former authors made a comparison with the ratio in the injected solution and the latter with liver. We chose blood, because this gives the closest comparison to an external photoscan of a patient when the activity in the blood pool is subtracted (Goldenberg et al., 1978; Dykes et al., 1980) . Demonstration of CEA in tumours and plasma.-CEA was demonstrated at the histological level in conventionally prepared tissue sections, using methods and reagents described previously (Heyderman & Neville, 1976; Ormerod, 1978) . In addition, the CEA content of xenografted tumours and in the plasmas of animals was measured by the radioimmunoassay methods of Laurence et al. (1972) . Each tumour was homogenized at 0°C in 0.9% saline. 2M perchloric acid was then added to each homogenate and the mixture was left at 00C for 30 min. Precipitated protein was removed by centrifugation and the supernatant was well dialysed with distilled water at 4°C. The radioimmunoassay was then performed.
Chromatography of plasma samples.-For the purpose of detecting CEA/anti-CEA complexes, each sample of plasma was applied to a column of Sephacryl S-300 (0.9 x 60 cm) and eluted with 01M phosphate buffer (pH 7.5) at a rate of 5 ml/h. 0(5ml fractions were collected and the radioactivity of each fraction (1251 and 1311) was measured using an LKB 1280 ultra-gamma counter.
RESULTS
Two to three weeks after tumour implantation (range of tumour wet wt 36-98 mg; mean 67 + 6 mg), the mice were injected i.v. with equal amounts by weight of 1251-labelled anti-CEA and 13l-labelled normal y-globulin. At each sampling time after injection at least 3 mice, carrying a total of 3-6 tumours, were exsanguinated and tumours and organs removed for estimation of the radioactivity. Altogether there were 10 experiments, using 211 animals carrying collectively 328 tumours. In addition, 2 nontumour-bearing animals, injected with the same amounts of antibodies, were exsanguinated at each sampling time. Table  I shows typical results for one of the tumours (HX99) 24 h after injection. It can be seen that the tumour was the only tissue which showed specific localization of the anti-CEA antibodies. This tumour was the only 1 of the 3 to show a high 
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1l0 degree of specific localization (Fig. 1) Fig. 1.) a 3rd injection on the 3rd day. These manoeuvres increased the activity in each tumour but at the expense of the localization index (Fig. 3) . When samples of plasma were passed over Sephacryl columns, the bulk of the radioactivity was eluted in a position corresponding to the mol. wt of IgG (Fig.  4) was greatly reduced in the profile of specific antibody obtained from the plasma of mice without tumours. We assume, although we did not prove it, that this voided material represents CEA-anti-CEA immune complexes. The peak of 1311-labelled normal Ig was normalized to coincide with the 125I peak and subtracted from it. The remaining 1251 activity was the voided material. We used this subtraction method to estimate the amount of radioactive material eluted as immune complex, and thereby followed the clearance of these complexes from the blood; there was no significant difference in the rate of clearance of immune complexes between mice bearing HX99 tumours (which gave a high localization index) and those bearing HX106 tumours (which gave no specific localization) (Fig.  5) . We observed that, in both tumourbearing and tumour-free mice, the specific (anti-CEA) IgG was cleared more rapidly in the first hour after injection than the nonspecific Ig. The specific 1251-labelled IgG also contained a small amount of aggregated material (Fig. 4) which was absent from the 131I-labelled nonspecific Ig. It is possible that the anti-CEA antibodies were more susceptible to damage during iodination, and that this resulted in an initial difference in behaviour between the two types of IgG.
To ascertain whether immune complexes of CEA and anti-CEA might localize in tumours through their content of histiocytes, we took C57 BL mice carrying a murine fibrosarcoma (FS6) (Mantovani et al., 1977) , which has a macrophage population of 25%, and administered both 14-12-10- 1251-labelled anti-CEA with CEA at equivalence and 1311-labelled goat Ig. No specific localization in the tumour was detected.
DISCUSSION
Other workers have successfully demonstrated the localization of specific anti-CEA antibodies in human colonic carcinoma xenografted either into hamsters (Primus et al., 1973) or into nude mice (Mach et al., 1974) . We have expanded this work by showing that anti-CEA antibodies will localize in human breast carcinomas.
The quantity of CEA circulating in the plasma of these mice will depend on the rate of synthesis and release of CEA by the tumour, and also on its rate of clearance. Our results suggest that the degree of localization of specific antibodies is dependent on the amount of CEA stored in the tumour, and that the amount of circulating CEA is irrelevant. The latter observation accords with the clinical experience recorded by Goldenberg and his co-workers (Goldenberg et at., Nagell et al., 1980; Primus et al., 1980) . This is important since it indicates that plasma CEA levels cannot be used to select patients for the application of this technique. The amount of CEA in the tumour as estimated either by an immunohistochemical stain or by extraction and subsequent radioimmunoassay may be a more reliable guide.
The results accord with the hypothesis that the anti-CEA antibodies are localized in the tumour by reaction with CEA at that site. In relation to this, we have shown by autoradiography that monoclonal antibodies raised to cell-surface antigens of human teratoma xenografts localize in close association to viable tumour cells after in vivo administration of the antibodies (Moshakis et al., 1981) .
Many tumours contain large numbers of histiocytes, and it could be visualized that specific antibodies would be localized in tumours, owing to uptake of immune complexes by the histiocytes. Although we looked for evidence to support this alternate hypothesis we found none. The levels of circulating immune complexes were similar in mice bearing HX99 tumours and those bearing HX106, yet one tumour showed a high degree of localization of specific antibody, whilst the other had none. Furthermore, anti-CEA alone and anti-CEA/CEA complexes failed to localize in a murine fibrosarcoma which is known to have a high percentage of macrophages in its cell population.
Although in this system, using these particular tumours, the localization index increased with time, the total amount of radioactivity in the tumours decreased. The optimal time at which to use an external radioscan in patients is balanced between the two factors. The other point to note is that at all times, apart from the tumour, the most radioactive tissue was the blood. This emphasizes the need for a technique to subtract the activity in the blood pool.
Having established the usefulness of this model system in relation to the wellknown antigen CEA, we are now in a position to extend this work to other less well studied antigens and to patients. Experiments have started using affinitypurified antibodies to the epithelial membrane antigen (EMA) expressed by human breast carcinomas (Heyderman et al., 1979; Sloane & Ormerod, 1981) and to teratomas, through the use of monoclonal antibodies (Moshakis et al., 1981) . We hope that this latter approach can, in time, be extended to the study of human breast carcinomas.
